Kids Favor Pump over Injections

NOVEMBER 01, 2003

    Investigators reported in Pediatrics (September 2003) that intensive insulin therapy is doable and safe for children with type 1 diabetes. A small study found that more children preferred treatment with continuous subcutaneous insulin infusion (CSII), compared with multiple daily insulin (MDI) injections. In the study, 23 participants, who ranged in age from 8 to 14 years, were randomly assigned to 1 of the 2 treatment methods. After receiving 1 treatment, the subjects were then switched to the other treatment.

    Glucose control increased significantly between an initial educational session and the start of the 7-month trial. At the end of the study, glucose levels did not differ significantly between treatment arms. Total daily insulin dose decreased, however, during CSII therapy and increased during MDI injections, according to the study results.



SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.